Table 3.

BAL cell types by H&E staining and by flow cytometry at days 2 and 4 after B1 or CP52 challenge of FI-RSV-immune mice treated with nIg F(ab)2 or anti-SP F(ab)2 Ab

Type of analysisImmunization + challenge + treatmentCell typebDay 2 p.i.Day 4 p.i.
Range, % positiveMedian % (P value)aRange, % positiveMedian % (P value)
H&E stainingFI-B1 + B1 + nIgMacrophage38–5044 (<0.01)40–5346 (<0.01)
PMN15–2018 (<0.01)6–1510 (<0.01)
Eosinophil19–3028 (<0.01)24–3830 (<0.01)
Lymphocyte8–1510 (<0.01)10–2214 (>0.10)
FI-B1 + B1 + anti-SPMacrophage88–9687 70–8475 
PMN00 2–115 
Eosinophil2–128 4–1610 
Lymphocyte4–125 2–1210 
FI-B1 + CP52 + nIgMacrophage88–9891 (>0.10)78–9082 (>0.10)
PMN0–11 (>0.10)0–105 (>0.10)
Eosinophil0–53 (>0.10)1–55 (>0.10)
Lymphocyte2–105 (>0.10)6–128 (>0.10)
FI-B1 + CP52 + anti-SPMacrophage90–9695 78–9488 
PMN00 0–22 
Eosinophil00 0–52 
Lymphocyte3–125 2–108 
Flow cytometryFI-B1 + B1 + nIgCD418–2524 (>0.10)22–2826 (>0.10)
CD85–810 (>0.10)5–108 (>0.10)
B2205–107 (>0.10)3–53 (>0.10)
DX55–128 (<0.01)5–1810 (<0.01)
RB6-8C55–106 (>0.10)7–1210 (>0.10)
FI-B1 + B1 + anti-SPCD418–2622 21–2624 
CD88–1010 5–118 
B2203–65 2–55 
DX514–2017 14–2520 
RB6-8C52–106 5–1210 
FI-B1 + CP52 + nIgCD422–2824 (>0.10)26–3028 (>0.10)
CD85–108 (>0.10)5–1410 (>0.10)
B2206–86 (<0.05)4–86 (>0.10)
DX514–2015 (>0.10)18–2520 (>0.10)
RB6-8C512–2014 (<0.01)20–2524 (<0.01)
FI-B1 + CP52 + anti-SPCD417–2221 25–2828 
CD86–1210 10–1512 
B2208–1210 6–128 
DX510–1814 17–2018 
RB6-8C55–108 6–109 
  • a Comparison between nIg and anti-SP-treated mice given the same challenge virus.

  • b A lymphocyte gate was used to select 10,000 events for CD3+ and B220+ lymphocytes; 10,000 ungated events were used for analysis of DX5+, RB6-8C5+, and CD11b+ cells.